CLR325
Total Payments
$754,530
Transactions
25
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $151,780 | 8 | 0 |
| 2018 | $283,166 | 9 | 1 |
| 2017 | $319,584 | 8 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $750,610 | 24 | 99.5% |
| Consulting Fee | $3,920 | 1 | 0.5% |
Payments by Type
Research
$750,610
24 transactions
General
$3,920
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED SUBJECT AND INVESTIGATOR BLIND PLACEBO CONTROLLED STUDY OF CLR325 IN CHRONIC STABLE HEART FAILURE PATIENTS | Novartis Pharmaceuticals Corporation | $750,610 | 0 |
Top Doctors Receiving Payments for CLR325
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Phila, PA | $750,610 | 24 |
| , MD | Cardiovascular Disease | Chicago, IL | $3,920 | 1 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $754,530
Product Information
- Type Drug
- Total Payments $754,530
- Total Doctors 1
- Transactions 25
About CLR325
CLR325 is a drug associated with $754,530 in payments to 1 healthcare providers, recorded across 25 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2019. In 2019, $151,780 was paid across 8 transactions to 0 doctors.
The most common payment nature for CLR325 is "Unspecified" ($750,610, 99.5% of total).
CLR325 is associated with 1 research study, including "A RANDOMIZED SUBJECT AND INVESTIGATOR BLIND PLACEBO CONTROLLED STUDY OF CLR325 IN CHRONIC STABLE HEART FAILURE PATIENTS" ($750,610).